Hospital
Riverview Hospital
Riverview Hospital was paid $7.90M by Medicaid between Jan 2018 and Nov 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoRIVERVIEW HOSPITAL
NOBLESVILLE, IN 46060
NOBLESVILLE, IN 46060
33aNPI1700883717assigned 07/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.90M
24GClaims188,980
24DCodes billed112
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#38 of 69
Median peer was paid$9.76M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,353 | $408K | |
| 2019 | 18,106 | $636K | |
| 2020 | 15,186 | $521K | |
| 2021 | 25,547 | $671K | |
| 2022 | 30,806 | $945K | |
| 2023 | 40,715 | $2.29M | |
| 2024incomplete | 33,267 | $2.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 16,734 | 13,790 | $2.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 15,701 | 13,881 | $1.98M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23% | 8,481 | 7,849 | $1.80M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 2,203 | 1,964 | $138K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 30,914 | 25,072 | $133K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 2,459 | 1,980 | $131K |
| 80053 | Comprehensive metabolic panel | 1.6% | 21,305 | 17,800 | $127K |
| 81513 | 1.1% | 830 | 750 | $91K | |
| 71045 | Radiologic examination, chest; single view | 1.1% | 685 | 582 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,482 | 4,998 | $65K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,751 | 3,895 | $60K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,043 | 1,777 | $58K |
100 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,043 | $58K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 662 | $57K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,459 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 569 | $52K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,985 | $51K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,564 | $50K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,922 | $46K |
| 80061 | Lipid panel | <1% | 4,774 | $45K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,430 | $42K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,627 | $42K |
| 62323 | <1% | 34 | $37K | |
| 99285 | Emergency room visit (most serious) | <1% | 174 | $28K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 264 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,580 | $24K |
| 87481 | <1% | 863 | $23K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 78 | $21K |
| 82607 | <1% | 1,627 | $19K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 45 | $17K |
| 86780 | <1% | 1,583 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 238 | $16K |
| 87563 | <1% | 556 | $15K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 133 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 138 | $9K |
| 83550 | <1% | 1,047 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 62 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 597 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 29 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 139 | $6K |
| 83540 | <1% | 1,047 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,230 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 925 | $5K |
| 83735 | <1% | 925 | $5K | |
| E0603 | Breast pump, electric (ac and/or dc), any type | <1% | 29 | $5K |
| 82746 | <1% | 335 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 17 | $4K |
| 80047 | <1% | 421 | $3K | |
| 85027 | <1% | 1,073 | $3K | |
| 84484 | <1% | 459 | $3K | |
| 87634 | <1% | 65 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 49 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 149 | $3K |
| 84702 | <1% | 316 | $3K | |
| 84439 | <1% | 342 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $2K |
| 82728 | <1% | 212 | $2K | |
| 81001 | <1% | 1,528 | $2K | |
| 87070 | <1% | 369 | $2K | |
| 59025 | Fetal non-stress test | <1% | 16 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 834 | $2K |
| 84144 | <1% | 119 | $2K | |
| 86803 | <1% | 204 | $2K | |
| 84481 | <1% | 124 | $2K | |
| 87510 | <1% | 191 | $2K | |
| 87660 | <1% | 191 | $2K | |
| 87480 | <1% | 191 | $2K | |
| 86706 | <1% | 191 | $1K | |
| 86850 | <1% | 371 | $1K | |
| 86696 | <1% | 94 | $1K | |
| 83690 | <1% | 529 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 29 | $1K |
| 81003 | <1% | 646 | $995.18 | |
| 86762 | <1% | 88 | $935.37 | |
| 87340 | <1% | 136 | $885.14 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 100 | $757.40 |
| 86695 | <1% | 63 | $593.55 | |
| 86376 | <1% | 48 | $582.88 | |
| 86901 | <1% | 266 | $500.08 | |
| 86900 | <1% | 266 | $500.08 | |
| 81025 | <1% | 133 | $484.64 | |
| 96132 | <1% | 17 | $414.12 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $343.83 |
| 83021 | <1% | 19 | $307.02 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $279.67 |
| 82950 | <1% | 72 | $267.71 | |
| 80164 | <1% | 26 | $178.42 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,410 | $173.77 |
| 82105 | <1% | 12 | $150.93 | |
| 84703 | <1% | 29 | $143.34 | |
| 82977 | <1% | 19 | $86.40 | |
| 82150 | <1% | 19 | $77.76 | |
| 84460 | <1% | 19 | $63.60 | |
| 84075 | <1% | 19 | $62.16 | |
| 84450 | <1% | 19 | $62.16 | |
| 82247 | <1% | 19 | $60.24 | |
| 82040 | <1% | 19 | $59.40 | |
| 84155 | <1% | 19 | $44.04 | |
| 82565 | <1% | 12 | $35.84 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 392 | $3.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 106 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 19 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 175 | $0.00 |
| 96139 | 0% | 17 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 18 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 49 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 22 | $0.00 |
| 96138 | 0% | 17 | $0.00 | |
| 96133 | 0% | 17 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 524 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 561 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 145 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHYATT, DAVE (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Riverview Hospital | Noblesville, IN | $9.10M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.